• Explore /
  • Poster
  • / A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).

A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Ashwin Somasundaram

The University of North Carolina at Chapel Hill, Chapel Hill, NC;

Ashwin Somasundaram , Paul R. Helft , William Proctor Harris , Hanna Kelly Sanoff , Guy E. Johnson , Menggang Yu , Matthew Johnson , Bert O'Neil , Autumn Jackson McRee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03099564

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 534)

DOI

10.1200/JCO.2023.41.4_suppl.534

Abstract #

534

Poster Bd #

C4

Abstract Disclosures

Similar Posters

First Author: Autumn Jackson McRee

First Author: Masatoshi Kudo

First Author: Jiayu Duan

First Author: Timothy J. Brown